The rst study to demonstrate a bene t of SGLT2 in- hibitors for HFrEF care examined the role of dapagli ozin in patients with HFrEF. The DAPA-HF study demon- strated that among 4,744 patients with HFrEF, the risk of worsening HF or death from CV causes was lower among those who received dapagli ozin than among those who received placebo, regardless of the presence or absence of T2D (16.3% in the dapagli ozin group versus 21.2% in the placebo group; hazard ratio: 0.74; 95% CI: 0.65 to 0.85). In addition, dapagli ozin demonstrated a signi cant reduc- tion in each of the individual components of the com- posite endpoint, with a 30% decrease in the risk of experiencing a rst episode of worsening HF (hospitali- zation for HF/urgent HF visit) and an 18% decrease in the risk of CV death (12). The DEFINE-HF (Dapagli ozin Effect on Symptoms and Biomarkers in Patients with HF) study demonstrated that dapagli ozin increased the proportion of patients experiencing clinically meaningful improve- ments in HF-related health status or natriuretic peptide concentrations in patients with HFrEF, regardless of the presence of diabetes (33). In the EMPEROR-Reduced trial in which 3,730 patients with chronic HFrEF were ran- domized to empagli ozin versus placebo, empagli ozin was found to signi cantly reduce the composite endpoint of CV death or HF hospitalization in adults with and without diabetes (19.4% in the empagli ozin group versus 24.7% in the placebo group; hazard ratio: 0.75; 95% CI: 0.65 to 0.86). The trial also showed that treatment with empagli ozin slowed the decline in the eGFR over time (13). 